2024-517095-38-00RecruitingPhase 2/3
Imaging multiple myeloma patients in the REMNANT study with Fluciclovine PET/CT (FLUCIPET)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To detect the number of patients in the REMNANT study who are positive with Fluciclovine PET/CT and negative with FDG PET/CT and determine how this correlate to PFS and OS
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 15 Oct 2024
- Start date
- 18 Dec 2023
- Lead sponsor
- Oslo University Hospital HF
- Diseases
- Multiple myeloma
- EU CT number
- 2024-517095-38-00
- EudraCT number
- 2022-003420-41
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 50
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma who are already in the REMNANT study Part 2 and can have an FDG PET/CT scan. They will also have a Fluciclovine PET/CT scan.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma, in people already enrolled in the REMNANT study Part 2.
Main reasons for not taking part
- Does not sign the consent or does not accept the study premises
- Hypersensitivity to the active substance or to any of the excipients
- Kidney problems where extra radiation is possible and the added risk is not acceptable
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hypersensitivity to the active substance or to any of the excipients
- Patients with renal impairment for whom an increased radiation exposure is possible, and the additional potential risk is considered not acceptable
Other
- Patients who do not sign the consent for any reason or do not accept the study premises
Who the study is looking for
- Patients who have been enrolled in the REMNANT study Part 2 and who are eligible for FDG PET/CT
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hospital HF | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.